Discover the revolutionary product developed by Demei Pharmaceutical Technology Co., Ltd. in collaboration with the leading pharmaceutical company Novo Nordisk - Liraglutide. Liraglutide is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is also used to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes mellitus and heart disease, This innovative medication works by stimulating the release of insulin and lowering glucagon secretion in a glucose-dependent manner. It also slows gastric emptying, leading to a reduction in appetite and food intake. Liraglutide is the first and only once-daily human Glucagon-Like Peptide-1 (GLP-analog approved by the FDA. Its efficacy and safety have been demonstrated in numerous clinical studies, making it a top choice for healthcare professionals in managing type 2 diabetes, With Demei Pharmaceutical Technology Co., Ltd.'s commitment to advancing healthcare through cutting-edge research and development, Liraglutide represents a significant milestone in the treatment of type 2 diabetes and cardiovascular risk reduction
Please feel free to give your inquiry in the form below We will reply you in 24 hours